Belal Kaseer
Interventional Cardiology · Royal Oak, MINPI 1518461755
Payments from drug & device makers
Across 91 payments — averaging $72.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$339
- Shockwave Medical, Inc$231
- AstraZeneca$188
- Abiomed$143
- plus $912 from 13 others
What the payments were for
- Grants$1,74526%
- Travel & lodging$1,26419%
- Food & beverage$2,93344%
- Education$66210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $2,564 |
| Boston Scientific | 10 | $2,227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $339 |
| Shockwave Medical, Inc | 2 | $231 |
| AstraZeneca | 6 | $188 |
| Abiomed | 2 | $143 |
| Johnson & Johnson | 4 | $133 |
| Novo Nordisk | 4 | $127 |
| Novartis | 6 | $123 |
| Esperion Therapeutics, Inc. | 1 | $113 |
| Stryker | 1 | $102 |
| Amgen | 1 | $86 |
| Teleflex LLC | 2 | $71 |
| Spectrawave, Inc | 1 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Cvrx, Inc. | 1 | $23 |
| Heartflow, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,255
- ENSITE$468
- AVVIGO Guidance System$437
- OPTIS$190
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$134
- NEXLIZET$113
- NEXLETOL$113
- FlowTriever$102
How this compares
$6,603 in reported general payments places this provider in the 40th percentile of 187 interventional cardiology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 18 | $24,005 |
| EliquisApixaban | 13 | $18,422 |
| FarxigaDapagliflozin Propanediol | 15 | $13,155 |
| JardianceEmpagliflozin | 20 | $12,605 |
| Ezetimibe | 19 | $541 |
| Atorvastatin Calcium | 44 | $360 |
| Metoprolol Succinate | 31 | $332 |
| Rosuvastatin Calcium | 26 | $163 |
| Amlodipine Besylate | 17 | $158 |
| Losartan Potassium | 14 | $85 |
| Metoprolol Tartrate | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $123 | $24,00518 claims |
| AstraZenecaFarxiga | $188 | $13,15515 claims |
| Boehringer IngelheimJardiance | $31 | $12,60520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Royal Oak
- Ryan MadderRoyal Oak$239K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.